Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA-3C: Aspirin and High-intensity Statin in Severe Coronary Calcification
NCT06676280Phase 4Recruiting
- Start
- Jul 2025
- Primary completion
- Mar 2035
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in atherosclerotic cardiovascular disease (ASCVD) (4 arms). Primary endpoint: Composite of Atherosclerotic Cardiovascular Disease Events at 3 years. Started Jul 2025; status: recruiting.
02
Drugs
aspirin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06676280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676280.